Characteristics of patients with haematological and breast cancer (1996–2009) who died of heart failure-related causes after cancer therapy

Vincent L. Versace1, Narelle M. Berry2, Munir H. Chowdhury2, Shahid Ullah3, Alexandra L. McCarthy4, John J. Atherton5, Bogda Koczwara6, David Roder7 and Robyn A. Clark2*

1School of Medicine, Deakin University, Warrnambool, VIC 3280, Australia; 2 School of Nursing and Midwifery, Flinders University, Adelaide, SA, Australia; 3Flinders Centre for Epidemiology and Biostatistics, School of Medicine, Flinders University, Adelaide, SA, Australia; 4Division of Cancer Services, Princess Alexandra Hospital, School of Nursing, Queensland University of Technology (QUT), Brisbane, Australia; 5Royal Brisbane and Women’s Hospital, Herston, QLD, Australia, 4029; 6Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, SA, Australia; 7Population Health Unit, School of Population Health, University of South Australia, Adelaide, SA, Australia

Abstract

Aims To describe the characteristics and time to death of patients with breast or haematological cancer who died of heart failure (HF) after cancer therapy. Patients with an index admission for HF who died of HF-related causes (IAHF) and those with no index admission for HF who died of HF-related causes (NIAHF) were compared.

Methods and results We performed a linked data analysis of cancer registry, death registry, and hospital administration records (n = 15 987). Index HF admission must have occurred after cancer diagnosis. Of the 4894 patients who were deceased (30.6% of cohort), 734 died of HF-related causes (50.1% female) of which 279 (38.0%) had at least one IAHF (41.9% female) post-cancer diagnosis. Median age was 71 years [interquartile range (IQR) 62–78] for IAHF and 66 years (IQR 56–74) for NIAHF. There were fewer chemotherapy separations for IAHF patients (median = 4, IQR 2–9) compared with NIAHF patients (median = 6, IQR 2–12). Of the IAHF patients, 71% had died within 1 year of the index HF admission. There was no significant difference in HF-related mortality in IAHF patients compared with NIAHF (HR, 1.10, 95% CI, 0.94–1.29, P = 0.225).

Conclusions The profile of IAHF patients who died of HF-related causes after cancer treatment matched the current profile of HF in the general population (over half were aged ≥70 years). However, NIAHF were younger (62% were aged ≤69 years), female patients with breast cancer that died of HF-related causes before hospital admission for HF-related causes—a group that may have been undiagnosed or undertreated until death.

Keywords Cardiotoxicity; Mortality; Haematological; Breast; Cancer; Heart failure

Received: 4 February 2016; Revised: 20 May 2016; Accepted: 30 May 2016
*Correspondence to: Robyn A. Clark PhD, School of Nursing and Midwifery, Flinders University, GPO Box 2100 Adelaide 5001, SA, Australia. Tel: +61 8 82013266. Email:robyn.clark@flinders.edu.au

Introduction

Anticancer therapies have increased recurrence-free survival for many patients with cancer. However, associated comorbidities and treatment-related toxicity have limited overall survival gains.1 Cardiotoxicity is one of the most significant side effects of some anticancer agents, so that any gain in life expectancy is potentially diminished by increased mortality because of cardiotoxic sequelae such as heart failure (HF), myocardial ischaemia, arrhythmias, hypertension, and thromboembolism.1 The incidence and outcomes of cardiotoxicity depend on different factors related to oncological therapies including the type of drug, the mode of administration (i.e. bolus or continuous), dose administered during each cycle, cumulative dose, combinations (or prior treatment) with other cardiotoxic

© 2016 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
drugs or radiotherapy of the cardiac region and patient age, mediastinal radiation, female sex, and presence of cardiovascular risk factors and previous cardiovascular disease.2,3

Cardiotoxicity related to anthracyclines is well documented, with early studies reporting variable rates, often based upon retrospective identification in cancer survivor cohorts. A recent large, prospective study, which included regular monitoring of cardiac function, reported an incident rate of cardiotoxicity following anthracycline therapy of 9% over a median 5-year follow-up period,3 with 98% of these cases occurring in the first 12 months. High mortality rates have also been reported in patients with anthracycline-mediated cardiotoxicity identified through historical longitudinal cohorts.4 More recent studies have suggested better cardiac-related survival of chemotherapy patients, especially in patients identified with pre-symptomatic left ventricular dysfunction.5 This is likely to be a result of routine baseline and ongoing monitoring being implemented as standard practice where known cardiotoxic drugs are considered.5 Cardinale et al. (2015) recently reported that left ventricular function either partially or completely recovered following early detection and treatment in 82% of patients with anthracycline-mediated cardiotoxicity.3 Torti and colleagues,6 based on histologic evidence of anthracycline cardiotoxicity, showed that only higher doses and frequency of anthracycline administration and previous cardiac irradiation were independent risk factors. Cumulative doxorubicin dose was also recently confirmed to be an independent risk factor by Cardinale et al. (2015), in addition to end-chemotherapy left ventricular ejection fraction. Nonetheless, there is wide variation in individual sensitivity to anthracyclines, with some patients developing cardiotoxicity at doses as low as 300 mg/m^2 body surface area.3

Previous work from our research group, using a linked dataset, demonstrated that in those individuals with breast or haematological cancer (leukaemias, lymphomas, and related blood disorders), 7% of patients previously treated with chemotherapy had an index hospital admission for HF (1062/15 987) within the 14-year study period (Figure 1).7 Of these patients who had an index admission for HF, 68% (728/1062) died within the study period, with 38%

---

**Figure 1** Population selection flow diagram. This diagram displays the initial study population through to the final study population.
(279/728) of deaths attributed to HF-related causes. Approximately 93% (14 925/15 987) of individuals did not have an index admission for HF following chemotherapy. Of these patients, 28% (4166/14 925) had died, with approximately 11% (455/4166) of deaths attributed to HF-related causes. Individuals who had no previous index HF admission were significantly younger and comprised a greater proportion of females compared with patients admitted with HF. This group was the focus of this study.

The aim of this sub-analysis was to further explore the characteristics of those patients who died of HF-related causes after chemotherapy. As 11% of the cohort described in the previously mentioned died of HF-related causes without an index hospital admission for HF, the objectives of this study were to

1. Identify differences in demographic characteristics between those who died of HF-related causes after an index admission for HF (IAHF), compared with those who died of HF-related causes without an index admission for HF (NIAHF) and
2. Identify whether there were differences in HF-related mortality risk between the two patient groups.

Methods

Study design and setting

This is a retrospective cohort study of patients linked using health data between January 1996 and December 2009 from Queensland, Australia. Queensland is Australia’s third most populous state with an estimated residential population of four million people during the study period. This time frame enabled linkage and analysis of uniform data across the three data sources relating to morbidity, hospitalization, and mortality.

Ethics approval was granted by the Metro South Service District Human Research Ethics Committee on behalf of the Queensland Government (HREC/11/QPAH/600).

Assumptions of this analysis

The purpose of this analysis was to review the characteristics of patients who died of HF after cancer treatment. We used ‘real-world’ data from clinical administration datasets using data linkage techniques. Data for cardiovascular risk factors, previous disease, and details on specific dose and chemotherapy agents were not available or obtainable during the process of data abstraction and linkage. Therefore, as a surrogate variable to control for confounders (such as a previous diagnosis of HF), we examined the outcomes of patients who had their first HF admission after chemotherapy. An index HF admission is the first-ever recorded admission as coded on discharge using ICD9 of International Classification of Diseases and Tenth Revision (ICD10) codes for the classification of HF. This is regarded as an acceptable criterion for diagnostic confirmation of HF. The comparison group may have contained patients with existing HF.

The second assumption of this analysis is that patients with breast or haematological cancers were more likely than patients with other cancers to be treated with cardiotoxic drugs, particularly anthracyclines.

Thirdly, while chemotherapy is usually delivered in the outpatient setting, ambulatory care of this nature is often recorded as an admission for chemotherapy, which we have used as a surrogate for the number of chemotherapy cycles. The assumption of this variable is that all patients in the cohort received chemotherapy for haematological and breast cancer from 1996 to 2009 but that not all chemotherapy cycles have been captured. Outpatient and pharmacotherapy data were not available for linkage at the time of our data request.

Participants

Primary cancer diagnosis was used to identify the cancer site/morphology using the ICD19 Australian Modification (ICD10-AM) and Oncology ICD-O site codes in the original linked dataset. Cancer sites were defined as breast (ICD10-AM: C50) or haematological (leukemia, lymphoma, and related disorders) (ICD10-AM: C42, C77 and ICD-O: M9590/3-M9989/3) henceforth referred to as ‘haematological cancers’. No age exclusions were applied. In this analysis, only patients who had died of HF-related causes were included, and these patients were then stratified into two groups—those who had their first admission/diagnosis for HF as identified by an IAHF and those who did not have an index HF admission (NIAHF), following commencement of chemotherapy.

Data sources and linkage

Data were accessed from the Queensland Cancer Registry, the Hospital Admitted Patient Data Collection, and the Queensland Births, Deaths, and Marriages database.

The Queensland Cancer Registry was used to access data on age, sex, marital status, residence (rural or metropolitan), country of birth, and Aboriginal or Torres Strait Islander status. Primary cancer diagnosis was used to identify the cancer type, and the cancer site/morphology was identified by applying the relevant site codes from ICD9 and ICD10.

Patients receiving chemotherapy were identified by using chemotherapy-related procedure codes from the Hospital Patient Data Collection and linked to the primary cancer diagnoses records from the Queensland Cancer Registry. The procedure codes were defined according to ICD Clinical Modification (ICD-9CM) and ICD10-AM. Cancer morphology codes were defined in accordance with uniform ICD-O. Radiotherapy was not considered in this study because of
the unknown proportion of patients receiving concomitant treatment in an outpatient setting.

Selection of patients with an index HF hospitalization was based upon hospital records with patients flagged if they had an admission to hospital for the first time with HF coded as the principle diagnosis (i.e. ICD9-CM and ICD10-AM diagnostic codes). This first admission or ‘index event’ must have occurred after the diagnosis of cancer and the commencement of chemotherapy.

The third database involved in the linkage process was the Queensland Birth, Deaths, and Marriages database—a complete repository of all registered deaths in the state of Queensland. All causes of death underwent a manual recoding from the text entries—a process that underwent quality assurance by three independent investigators. The end date of data for study purposes was 31 December 2009. Deaths after this date were not accounted for, and the patients alive at the specified end date were considered alive for the purposes of calculating survival times and mortality analyses. Data extraction and coding were undertaken using STATA 13.0. Linkage Wiz software was used to undertake probabilistic record matching. Quality control undertaken during the linkage process included a 20-step recoding from the text entries—a method that quantified the false positive rate at 0.3%.9

Statistical analyses

Based upon the stratification of patients as (i) an index HF admission (IAHF) and (ii) no admission for HF (NIAHF), admission groups were compared using χ²-contingency table testing for categorical variables (age group, sex marital status, country of birth, Indigenous status, residence, cancer morphology/site). Age in years was categorized as <20, 20–29, 30–39, 40–49, 50–59, 60–69, and ≥70 to describe the demographics of the study population and is also presented as a continuous variable. Because of the non-normal distribution of the continuous variables (age, hospitalizations, chemotherapy treatments), they are presented as medians with interquartile range (IQR) and compared using the non-parametric Mann–Whitney U test. The effect of an IAHF on the risk of HF mortality was assessed adjusted for age, sex, marital status, country of birth, cancer site, and chemotherapy along with other confounders using a time-adjusted Cox proportional hazards regression model. Multivariate adjustment was undertaken for the covariates of age group in years [<20, 20–29, 30–39, 40–49, 50–59, 60–69, and ≥70], sex, marital status, country of birth, cancer site, and number of chemotherapy separations categorized as quintiles [Q1: 1–3; Q2: 4–6; Q3: 7–9; Q4: 10–16; Q5: ≥17]. To examine associations between admission groups, an adjusted Kaplan–Meier survival analysis was used with a log-rank test. All statistical tests were conducted at the 5% significance level and were performed using IBM SPSS 22.0.

Results

Participants

A Strengthening the Reporting of Observational studies in Epidemiology flow chart describes the allocation of patients to the respective groups for the subsequent analyses (Figure 1).10 A total of 73 158 patients from the cancer registry were able to be record-matched with hospital administration records and mortality data.

Of these, 918 were diagnosed with multiple cancers. To avoid duplicating patients in the analyses, the primary cancer diagnosis was chosen and the remaining registrations of subsequent cancers in this group were excluded (n = 927). A further 15 750 were excluded as they fell outside the study time period, and another 40 494 were excluded as they did not receive chemotherapy.

The remaining 15 987 patients were then identified as those who had an index HF admission (n = 1062) or those who did not have an index HF admission (n = 14 925).

Within each of these groups, those with HF-related death within the study period were identified, resulting in the two groups analysed in this study: those with a diagnosed index HF admission who died of HF-related causes (IAHF, n = 279) and those with no index HF admission but who died of HF-related causes (NIAHF, n = 455).

Demographics and characteristics

Within the deceased group, the median age at cancer diagnosis was 71 and 66 years for the IAHF and NIAHF patients, respectively (Table 1, P < 0.001). There was a significant association between age group and HF admission status between these two groups, with the majority of HF patients being ≥70 years, while the NIAHF were more evenly spread across the younger age groups (χ² = 32.05, df = 6, P < 0.001). Gender (χ² = 12.11, df = 1, P = 0.001) and cancer morphology/site (χ² = 25.57, df = 1, P < 0.001) were also significantly different between the two groups, as were the median number of overall hospitalizations for HF or chemotherapy (P < 0.001) and median number of chemotherapy admissions (P < 0.001). All other comparisons were non-significant.

Outcomes

There was no significant difference in HF-related mortality in IAHF patients compared with NIAHF (HR, 1.10, 95% CI, 0.94–1.29, P = 0.225) (Figure 2) when adjusted for age, sex, marital status, country of birth, cancer site, and number of chemotherapy treatments.

In the NIAHF group, individuals diagnosed with haematological cancer were almost 1.5 times more likely to die of HF-related causes than patients with breast cancer (P = 0.006) (Table 2).
A similar odds ratio was evident in the IAHF patients but was non-significant. The only other significant difference was that those in the IAHF group received four to six admissions for chemotherapy compared with those who had one to three admissions (Table 2). All other covariates were non-significant in the adjusted models.

Of those who died of HF-related causes, 31% of IAHF and 33% of NIAHF patients died within the first year after the cancer diagnosis and 60% of IAHF and 62% of NIAHF patients had died of HF-related causes within 3 years of cancer registration.

Of note, of the IAHF patients, 70.6% of patients had died of HF-related causes within the first year following their HF diagnosis.

### Discussion

In this analysis of linked hospital administration data, we have examined the patient journey through cancer diagnosis, chemotherapy, and the onset of HF and ultimately HF-related death. We have described and compared individuals who had an index HF hospital admission (IAHF) with those who did not have an index HF hospital admission (NIAHF) following chemotherapy. All of the patients included in the analyses died of HF-related causes. Specifically, we were interested in those patients who died of HF-related causes but were not newly diagnosed (index admission) or already had a HF diagnosis. When comparing characteristics of the IAHF and NIAHF patients, the median age and gender differences for the IAHF patients had similar demographical characteristic to HF in the non-cancer population. That is, the study group had a similar median age and a greater proportion of men. In contrast, NIAHF patients were younger and had a greater proportion of female patients than males. In addition, there was a greater proportion of patients with breast cancer in the NIAHF patients compared with the IAHF group. Collectively, our results indicated that younger, female patients with breast cancer died of HF-related causes before hospital admission for HF-related causes.

The first year following an index HF admission saw the highest mortality, with 71% of individuals dying of HF-related causes in that period. The first year after cancer diagnosis showed very similar proportions of patients in both groups dying from HF-related causes (30.5 and 33.4% in the IAHF and NIAHF, respectively). Without supplementary information (refer to the Strengths and limitations section in the succeeding texts), it is difficult to further explore this finding in more depth. It may be that IAHF patients are symptomatic.
and mortality is high shortly after admission. A possible explanation of similar mortality in NIAHF (typically younger patients) is a higher tolerance of HF symptoms and as such were not admitted to hospital, and sudden death followed because of arrhythmia. Nonetheless, our results are comparable with other studies that have demonstrated that 38% of patients with a HF diagnosis had died within 12 months.\textsuperscript{12}

Although not statistically significant, the risk of crude HF mortality was about 10% higher for individuals not admitted to hospital with HF compared with those admitted with HF. Whilst it may seem counterintuitive, and one might expect the NIAHF group to have a lower proportion of mortality because of HF, a possible explanation could be that those diagnosed with HF received some intensive cardiac interventions that reduced their mortality.

**Figure 2** Time to HF-related death after cancer diagnosis between those who had an index admission for HF (IAHF, $n = 279$) compared with those who did not (NIAHF, $n = 455$).

![Figure 2](image)

**Table 2** Adjusted time-varying Cox proportion hazards model for HF-related mortality of chemotherapy receiving patients with haematological and breast cancer by index admission for HF

| Parameter | Patient with index HF admission | Patient with no HF admission |
|-----------|---------------------------------|-----------------------------|
|           | HR (95% CI)                      | P\textsuperscript{*}        | HR (95% CI)                      | P\textsuperscript{*}        |
| Age       |                                 |                             |                                 |                             |
| <20 years\textsuperscript{a} | 0.30 (0.02–5.08) | 0.408 | 0.56 (0.13–2.38) | 0.425 |
| 20–29 years | 0.26 (0.03–2.56) | 0.246 | 0.47 (0.14–1.67) | 0.245 |
| 30–39 years | 0.33 (0.04–2.66) | 0.295 | 0.49 (0.15–1.61) | 0.240 |
| 40–49 years | 0.35 (0.05–2.64) | 0.307 | 0.57 (0.18–1.83) | 0.343 |
| 50–59 years | 0.46 (0.06–3.40) | 0.447 | 0.44 (0.14–1.40) | 0.165 |
| 60–69 years | 0.44 (0.06–3.19) | 0.413 | 0.50 (0.16–1.58) | 0.237 |
| ≥70 years  | 1.22 (0.89–1.68) | 0.221 | 0.96 (0.75–1.23) | 0.754 |
| Sex       |                                 |                             |                                 |                             |
| Female vs. male | 0.96 (0.72–1.29) | 0.802 | 0.98 (0.80–1.21) | 0.869 |
| Marital status | 0.86 (0.65–1.14) | 0.303 | 1.15 (0.92–1.44) | 0.214 |
| Country of birth | 1.47 (0.97–2.23) | 0.068 | 1.48 (1.11–1.95) | 0.006 |
| Cancer site |                                 |                             |                                 |                             |
| Breast vs. haematological | 0.91 (0.83–0.99) | 0.027 | 0.97 (0.90–1.05) | 0.420 |
| Chemotherapy separations (quintiles) | 0.93 (0.83–1.02) | 0.152 | 0.94 (0.87–1.01) | 0.102 |
| 4–6 | 0.92 (0.84–1.02) | 0.108 | 0.98 (0.91–1.06) | 0.684 |
| 7–9 | 0.95 (0.86–1.06) | 0.364 | 0.97 (0.90–1.05) | 0.479 |

HF, heart failure; HR, hazard ratio.

\textsuperscript{a}Reference category.

Data were adjusted for age, sex, marital status, country of birth, cancer site, and time-dependent number of chemotherapy treatment.

*Statistically significant at $P \leq 0.05$. 

ESC Heart Failure 2016; 3: 253–260
DOI: 10.1002/ehf2.12099
risk in the first year. It is possible that extracardiac treatment is also responsible for comparable proportions of mortality because of HF at the end of 3 years also (60 and 62% in the IAHF and NIAHF, respectively). These mortality rates are all substantially higher, within all age groups within this cohort, than those reported in the most recent epidemiological studies for HF in the general population where, although survival has improved, the absolute mortality rates for HF remain approximately 50% within 5 years of diagnosis.\textsuperscript{13,14} In the ARIC study, the 30-day, 1-year, and 5-year case fatality rates after hospitalization for HF were 10.4, 22, and 42.3%, respectively.\textsuperscript{15}

Over the course of their treatment, IAHF patients received significantly fewer chemotherapy treatments than the NIAHF group. This trend could be attributed to clinical adherence to cardiotoxicity treatment guidelines, with a commensurate reduction in cumulative chemotherapy dose or complete cessation of treatment after HF was identified.\textsuperscript{5} However, in the context of a retrospective observational study, there are numerous confounders that were beyond our control that would need to be accounted for to definitively conclude if this was the case. In addition, we may need to consider that current available therapies for HF administered earlier in the chemotherapy treatment phase are of limited efficacy. Also, our outcomes may be indicating that the admission index was a poor surrogate for efficacy of early introduction of effective therapies.

**Strengths and limitations**

The strengths of this study are the large sample size and the inclusion of virtually all patients with cancer who underwent chemotherapy over a 14-year period. The ability to link administrative datasets allows for the integration of multiple databases to provide a comprehensive picture of patient outcomes. However, potential limitations should be considered.

The nature of this type of study method means that what is gained in overall numbers of patients comes at the expense of detailed case information. The direct implication of this is that numerous confounding factors cannot be accounted for. For example, the absence of information regarding the cancer treatment, including the precise chemotherapy drugs used and the site and extent of irradiation, plus radiotherapy and the lack of information about pre-existing cardiovascular risk factors or established heart disease prevents us from understanding the association of specific treatments and the subsequent development of HF. Furthermore, in the absence of supplementary data, we are unable to elucidate the causes of HF-related deaths (e.g. was death as a result of advanced cardiomyopathy, cardiogenic shock, arrhythmia, or electrolyte imbalance because of diuretics?) or the severity of HF status. These limitations were because of only being able to access datasets with custodian approval, and in an idealized situation, more relevant data would have been incorporated in the analysis framework (e.g. whether patients were administered appropriate and optimal HF medications). In the absence of this data, we included chemotherapy separations as a surrogate for drug information. The gender balance in our study is not representative of the general population with 31% of the sample being male and 69% female. The inclusion of patients with breast cancer has resulted in an over-representation of female patients.

**Clinical implications**

Current Clinical Practice Guidelines for cardiovascular toxicity after chemotherapy and radiotherapy from the European Society of Medical Oncology (ESMO) recommend that patients are frequently monitored for cardiovascular risk before, during, and after treatment.\textsuperscript{5} These guidelines state that both cardiovascular risk factor screening and heart structure and function monitoring, including appropriate cardiovascular intervention, should occur prior to cancer treatment. In addition, cardiac monitoring should continue at baseline, 3, 6, and 9 months during treatment, and further monitoring should be undertaken at 12 and 18 months and followed up at 4 and 10 years. In the present study, we have identified that HF-related death can occur rapidly after cancer treatment in individuals diagnosed with cancers in which cardiotoxic drugs are often prescribed. This finding is consistent with the ESMO recommendations of ongoing cardiac monitoring, and it is likely with ongoing frequent monitoring appropriate intervention can be implemented to decrease HF-related mortality after cancer therapy.

**Conclusions**

The profile of patients who died of HF-related causes who had an IAHF after cancer treatment matched the current profile of HF in the general population (over half were aged ≥70 years). However, the group that did not have an index admission for HF were younger (62% were aged ≤69 years), females with breast cancer. In this group, HF after cancer therapy may have been underdiagnosed or undertreated until death, and the HF caused by the chemotherapy may manifest long after discharge from cancer care.

**Acknowledgements**

The research work was supported by the Institute of Health and Biomedical Innovation of Queensland University of Technology under Collaborative Research Development Grant Scheme 2011 and a Flinders University Faculty of Health Sciences Seeding grant 2013.
Conflict of interest

None declared.

References

1. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53: 2231–2247.
2. Bovelli D, Plataniotis G, Roila F. ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21: v277–v282.
3. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015; 131: 1981–1988.
4. Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voûte PA. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001; 19: 191–196.
5. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri M, Criscitiello C, Goldhirsh A, Cipolla C, Roila F, on behalf of the ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2012; 23: vii155–vii166.
6. Torti FM, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SR, Kohler M, Brown BW Jr,Billingham ME. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: assessment by endomyocardial biopsy. Ann Intern Med 1983; 99: 745–749.
7. Clark RA, McCarthy A, Chowdhury MH, Berry NM, Ullah S, Koczwar B, Roder D. Abstract 12134: demographics and survival of a cohort of blood and breast cancer patients who developed heart failure following cancer treatment. Circulation 2014; 130: A12134.
8. ABS. Queensland (STE), Community Profile: Australian Bureau of Statistics; 2006 Available from: http://www.censusdata.abs.gov.au/census_services/getproduct/census/2006/quickstat/3?opendocument&navpos=220 (23/10/2014).
9. Centre for Health Record Linkage. Master Linkage Key (MLK) Quality Assurance: Centre for Health Record Linkage; 2012. Available from: http://www.cherel.org.au/media/24160/qa_report_2012.pdf (22/10/2014).
10. Vanderbroucke JP, Von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schleselman JJ, Egger M, for the STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007; 147: W163–W194.
11. Cowie MR, Wood DA, Coats AJS, Thompson SG, Poole-Wilson PA, Suresh V, Sutton GC. Incidence and aetiology of heart failure; a population-based study. Eur Heart J 1999; 20: 421–428.
12. Cowie MR, Wood DA, Coats AJS, Thompson SG, Suresh V, Poole-Wilson PA, Sutton GC. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 2000; 83: 505–510.
13. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ. Trends in heart failure incidence and survival in a community-based population. JAMA 2004; 292: 344–350.
14. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397–1402.
15. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol 2008; 101: 1016–1022.